Synergistic Combination of Perphenazine and Temozolomide Suppresses Patient-Derived Glioblastoma Tumorspheres

Academic Background Glioblastoma (GBM) is a highly malignant primary brain tumor. Despite current standard treatments such as surgical resection, radiotherapy, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 14.6 months. Traditional treatments often fail to completely eradicate the tumor and are prone to recur...